Molecular Mechanism Study on the Expression of TF-MPs in Cervical Cancer Patients and Deep Venous Thrombosis

Objective: To explore the molecular mechanism of tissue factor-positive microparticles (TF-MPs) expression and deep venous thrombosis (DVT) in patients with cervical cancer. Methods: A total of 200 patients with cervical cancer and benign cervical diseases who were hospitalized in the First Department of Gynecologic Oncology of Gansu Provincial Cancer Hospital from January 2024 to December 2025 were selected, including 100 patients with benign cervical diseases as the control group and 100 patients with cervical cancer as the experimental group. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression level of TF-MPs in peripheral blood samples from patients with cervical cancer and healthy controls. At the same time, real-time quantitative PCR was used to explore the molecular mechanism of TF-MPs promoting DVT formation. Finally, the formation of DVT in the two groups was observed and recorded, and the incidence of DVT was counted. Results: Experimental measurements showed that the expression levels of TF-MPs, coagulation factors FVII, FX, PT, and inflammatory factors IL-6 and TNF-a in the experimental group were significantly higher than those in the control group (P < 0.01); the incidence of DVT in the experimental group was up to 38%, far exceeding the 6% in the control group (P < 0.001). Conclusion: Abnormal expression of TF-MPs in patients with cervical cancer is an important risk factor for DVT. Through in-depth analysis of the molecular mechanism of TF-MPs promoting DVT formation, it provides a new perspective and theoretical basis for the prevention and treatment of DVT in patients with cervical cancer. In the future, intervention strategies targeting TF-MPs and their related molecular pathways are expected to become effective ways to reduce the incidence of DVT in patients with cervical cancer.